文献速递妇科

子宫内膜异位症中的化疗敏感性与化疗耐药性——异位与在位细胞的差异

Chemosensitivity and chemoresistance in endometriosis - differences for ectopic versus eutopic cells.
PubMed 文献 · Reprod Biomed Online · 2019-05-31

本研究在11例患者的配对在位与异位子宫内膜间质细胞中检测14种化合物对细胞活力的影响,发现蛋白激酶抑制剂GSK690693、ARC-775、索拉非尼、蛋白酶体抑制剂硼替佐米和微管解聚毒素单甲基澳瑞他汀E对在位细胞更有效,而10 µmol/l多柔比星对异位细胞更有效。mRNA测序提示在位与异位子宫内膜存在不同生存策略,异位细胞存在大规模代谢重编程,多柔比星干扰氧化还原平衡和/或DNA修复机制的高效性可能用于选择性靶向异位病灶。

要点

  • 蛋白激酶抑制剂和硼替佐米对在位子宫内膜间质细胞更有效。
  • 10 µmol/l多柔比星对异位细胞杀伤效果优于在位细胞。
  • 异位子宫内膜细胞存在大规模代谢重编程,生存策略不同。

核心结论

  • 结果证实异位子宫内膜细胞存在大规模代谢重编程,这构成其对毒素敏感性差异的基础。
  • 多柔比星干扰氧化还原平衡和/或DNA修复机制的高效性,可能用于选择性靶向子宫内膜异位症异位病灶。

研究设计与样本

  • 在11例患者的配对在位与异位子宫内膜间质细胞样本中检测14种化合物对细胞活力的影响。
  • 化合物面板覆盖促生存酶、细胞骨架蛋白、蛋白酶体和细胞修复机制等生物靶点。

主要发现

  • 蛋白激酶抑制剂GSK690693、ARC-775和索拉非尼对在位细胞更有效。
  • 蛋白酶体抑制剂硼替佐米对在位细胞更有效。
  • 微管解聚毒素单甲基澳瑞他汀E对在位细胞更有效。
  • 10 µmol/l多柔比星对异位细胞致细胞死亡的效果优于在位细胞。
  • 对多柔比星处理细胞与对照细胞进行mRNA大规模测序,提示在位与异位子宫内膜存在不同生存策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Endometriosis is a common gynaecological disease defined by the presence of endometrium-like tissue outside the uterus. This complex disease, often accompanied by severe pain and infertility, causes a significant medical and socioeconomic burden; hence, novel strategies are being sought for the treatment of endometriosis. Here, we set out to explore the cytotoxic effects of a panel of compounds to find toxins with different efficiency in eutopic versus ectopic cells, thus highlighting alterations in the corresponding molecular pathways. DESIGN: The effect on cellular viability of 14 compounds was established in a cohort of paired eutopic and ectopic endometrial stromal cell samples from 11 patients. The biological targets covered by the panel included pro-survival enzymes, cytoskeleton proteins, the proteasome and the cell repair machinery. RESULTS: Protein kinase inhibitors GSK690693, ARC-775 and sorafenib, proteasome inhibitor bortezomib, and microtubule-depolymerizing toxin monomethyl auristatin E were more effective in eutopic cells. In contrast, 10 µmol/l of the anthracycline toxin doxorubicin caused cellular death in ectopic cells more effectively than in eutopic cells. The large-scale sequencing of mRNA isolated from doxorubicin-treated and control cells indicated different survival strategies in eutopic versus ectopic endometrium. CONCLUSIONS: Overall, the results confirm evidence of large-scale metabolic reprogramming in endometriotic cells, which underlies the observed differences in sensitivity towards toxins. The enhanced efficiency of doxorubicin interfering with redox equilibria and/or DNA repair mechanisms pinpoints key players that can be potentially used to selectively target ectopic lesions in endometriosis.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Lavogina D, Samuel K, Lavrits A, et al. Chemosensitivity and chemoresistance in endometriosis - differences for ectopic versus eutopic cells. Reprod Biomed Online. 2019. PMID: 31377021. doi:10.1016/j.rbmo.2019.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。